| Sep 19 |
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
|
| Sep 9 |
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 4 |
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
|
| Sep 3 |
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
|
| Aug 15 |
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
|
| Aug 14 |
Genprex stock slides 14% following Reqorsa study updates
|
| Aug 14 |
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
|
| Aug 13 |
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
|
| Aug 8 |
Genprex to Present at the August Sidoti Microcap Conference
|
| Jun 27 |
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
|
